• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于疾病风险评分的混杂因素调整对多个感兴趣结局的扩展:一项实证评估。

Extension of Disease Risk Score-Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation.

机构信息

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.

出版信息

Am J Epidemiol. 2018 Nov 1;187(11):2439-2448. doi: 10.1093/aje/kwy130.

DOI:10.1093/aje/kwy130
PMID:29947726
Abstract

Use of disease risk score (DRS)-based confounding adjustment when estimating treatment effects on multiple outcomes is not well studied. We designed an empirical cohort study to compare dabigatran initiators and warfarin initiators with respect to risks of ischemic stroke and major bleeding in 12 sequential monitoring periods (90 days each), using data from the Truven Marketscan database (Truven Health Analytics, Ann Arbor, Michigan). We implemented 2 approaches to combine DRS for multiple outcomes: 1) 1:1 matching on prognostic propensity scores (PPS), created using DRS for bleeding and stroke as independent variables in a propensity score (PS) model; and 2) simultaneous 1:1 matching on DRS for bleeding and stroke using Mahalanobis distance (M-distance), and compared their performance with that of traditional PS matching. M-distance matching appeared to produce more stable results in the early marketing period than both PPS and traditional PS matching; hazard ratios from unadjusted analysis, traditional PS matching, PPS matching, and M-distance matching after 4 periods were 0.72 (95% confidence interval (CI): 0.51, 1.03), 0.61 (95% CI: 0.31, 1.09), 0.55 (95% CI: 0.33, 0.91), and 0.78 (95% CI: 0.45, 1.34), respectively, for stroke and 0.65 (95% CI: 0.53, 0.80), 0.78 (95% CI: 0.60, 1.01), 0.75 (95% CI: 0.59, 0.96), and 0.78 (95% CI: 0.64, 0.95), respectively, for bleeding. In later periods, estimates were similar for traditional PS matching and M-distance matching but suggested potential residual confounding with PPS matching. These results suggest that M-distance matching may be a valid approach for extension of DRS-based confounding adjustments for multiple outcomes of interest.

摘要

使用基于疾病风险评分(DRS)的混杂调整来估计多种结局的治疗效果在研究中尚不完善。我们设计了一项实证队列研究,使用 Truven Marketscan 数据库(密歇根州安阿伯市 Truven Health Analytics)的数据,比较了达比加群酯和华法林的起始治疗者在 12 个连续监测期(每个 90 天)内缺血性中风和大出血的风险。我们实施了两种方法来合并多个结局的 DRS:1)基于预后倾向评分(PPS)的 1:1 匹配,使用 DRS 对出血和中风作为倾向评分(PS)模型中的独立变量来创建;2)同时使用 Mahalanobis 距离(M-距离)对出血和中风的 DRS 进行 1:1 匹配,并比较其与传统 PS 匹配的性能。在早期市场推广阶段,M-距离匹配似乎比 PPS 和传统 PS 匹配产生更稳定的结果;未经调整的分析、传统 PS 匹配、PPS 匹配和 M-距离匹配 4 个周期后的风险比分别为 0.72(95%置信区间:0.51,1.03)、0.61(95%置信区间:0.31,1.09)、0.55(95%置信区间:0.33,0.91)和 0.78(95%置信区间:0.45,1.34),用于中风;0.65(95%置信区间:0.53,0.80)、0.78(95%置信区间:0.60,1.01)、0.75(95%置信区间:0.59,0.96)和 0.78(95%置信区间:0.64,0.95),用于大出血。在后期,传统 PS 匹配和 M-距离匹配的估计值相似,但提示 PPS 匹配可能存在潜在的残余混杂。这些结果表明,M-距离匹配可能是一种有效的方法,可以扩展基于 DRS 的混杂调整,以用于感兴趣的多个结局。

相似文献

1
Extension of Disease Risk Score-Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation.基于疾病风险评分的混杂因素调整对多个感兴趣结局的扩展:一项实证评估。
Am J Epidemiol. 2018 Nov 1;187(11):2439-2448. doi: 10.1093/aje/kwy130.
2
Matching on the disease risk score in comparative effectiveness research of new treatments.在新疗法的比较效果研究中对疾病风险评分进行匹配。
Pharmacoepidemiol Drug Saf. 2015 Sep;24(9):951-61. doi: 10.1002/pds.3810. Epub 2015 Jun 25.
3
Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin.在达比加群与华法林的一项研究中,倾向评分加权与匹配的比较
Drug Saf. 2017 Feb;40(2):169-181. doi: 10.1007/s40264-016-0480-3.
4
Evaluation of propensity scores, disease risk scores, and regression in confounder adjustment for the safety of emerging treatment with group sequential monitoring.在序贯组监测中对新兴治疗安全性进行混杂因素调整时,倾向得分、疾病风险评分及回归的评估。
Pharmacoepidemiol Drug Saf. 2016 Apr;25(4):453-61. doi: 10.1002/pds.3983. Epub 2016 Feb 15.
5
Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.口服抗凝剂在新诊断房颤老年患者中的性别特异性比较疗效
Circ Cardiovasc Qual Outcomes. 2017 Apr;10(4). doi: 10.1161/CIRCOUTCOMES.116.003418.
6
Comparison of Calipers for Matching on the Disease Risk Score.用于疾病风险评分匹配的卡尺比较
Am J Epidemiol. 2016 May 15;183(10):937-48. doi: 10.1093/aje/kwv302. Epub 2016 Apr 1.
7
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.达比加群、利伐沙班和阿哌沙班与华法林相比治疗非瓣膜性心房颤动的有效性和安全性。
J Am Heart Assoc. 2016 Jun 13;5(6):e003725. doi: 10.1161/JAHA.116.003725.
8
Studies with many covariates and few outcomes: selecting covariates and implementing propensity-score-based confounding adjustments.具有众多协变量和较少结局的研究:选择协变量并实施基于倾向评分的混杂调整。
Epidemiology. 2014 Mar;25(2):268-78. doi: 10.1097/EDE.0000000000000069.
9
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.非瓣膜性心房颤动患者应用阿哌沙班、达比加群、利伐沙班或华法林起始抗凝治疗的大出血风险的真实世界比较:倾向评分匹配分析。
Thromb Haemost. 2016 Oct 28;116(5):975-986. doi: 10.1160/TH16-05-0403. Epub 2016 Aug 19.
10
'Real-world' haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand.利用新西兰人群水平数据得出的华法林和达比加群的“真实世界”出血率。
Int J Cardiol. 2016 Jan 15;203:746-52. doi: 10.1016/j.ijcard.2015.11.067. Epub 2015 Nov 10.

引用本文的文献

1
Confounder Adjustment Using the Disease Risk Score: A Proposal for Weighting Methods.使用疾病风险评分进行混杂因素调整:加权方法建议
Am J Epidemiol. 2024 Feb 5;193(2):377-388. doi: 10.1093/aje/kwad196.
2
Association of injury after prescription opioid initiation with risk for opioid-related adverse events among older Medicare beneficiaries in the United States: A nested case-control study.美国老年医疗保险受益人中处方类阿片类药物使用后损伤与阿片类药物相关不良事件风险的关联:一项巢式病例对照研究。
PLoS Med. 2022 Sep 22;19(9):e1004101. doi: 10.1371/journal.pmed.1004101. eCollection 2022 Sep.
3
Health Effects of Religion, Spirituality, and Supernatural Beliefs in Mainland China: A Systematic Review.
中国大陆的宗教、精神和超自然信仰对健康的影响:系统综述。
J Relig Health. 2022 Aug;61(4):2726-2742. doi: 10.1007/s10943-022-01543-3. Epub 2022 Mar 26.
4
Disparities by sex in P2Y inhibitor therapy duration, or differences in the balance of ischaemic-benefit and bleeding-risk clinical outcomes in older women versus comparable men following acute myocardial infarction? A P2Y inhibitor new user retrospective cohort analysis of US Medicare claims data.在急性心肌梗死后,老年女性与可比男性相比,P2Y 抑制剂治疗持续时间是否存在性别差异,或者缺血获益和出血风险临床结局的平衡是否存在差异?利用美国医疗保险索赔数据的 P2Y 抑制剂新使用者回顾性队列分析。
BMJ Open. 2021 Dec 1;11(12):e050236. doi: 10.1136/bmjopen-2021-050236.
5
Standardizing Discrete-Time Hazard Ratios With a Disease Risk Score.用疾病风险评分标准化离散时间风险比。
Am J Epidemiol. 2020 Oct 1;189(10):1197-1203. doi: 10.1093/aje/kwaa061.
6
Association Between Proton Pump Inhibitor Use and Risk of Fracture in Children.质子泵抑制剂的使用与儿童骨折风险的关联。
JAMA Pediatr. 2020 Jun 1;174(6):543-551. doi: 10.1001/jamapediatrics.2020.0007.
7
Surgical necrotizing enterocolitis but not spontaneous intestinal perforation is associated with adverse neurological outcome at school age.手术性坏死性小肠结肠炎而非自发性肠穿孔与学龄期不良神经结局相关。
Sci Rep. 2020 Feb 11;10(1):2373. doi: 10.1038/s41598-020-58761-6.